VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Overview Fund Activity
Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

68 hedge funds and large institutions have $62.3M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 12 closing their positions.

Holders
68
Holders Change
–
Holders Change %
0%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
13
Reduced
22
Closed
12
Calls
$934K
Puts
$287K
Net Calls
+$647K
Net Calls Change
+$845K

Top Buyers

1
MCM
1
MAI Capital Management
Ohio
$1.81M
2
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$1.21M
3
BI
3
BVF Inc
California
$17.2M
4
BCM
4
Bridgeway Capital Management
Texas
$333K
5
Citadel Advisors
5
Citadel Advisors
Florida
$7.45M

Top Sellers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.95M
2
Morgan Stanley
2
Morgan Stanley
New York
$322K
3
Royal Bank of Canada
3
Royal Bank of Canada
Ontario, Canada
$11K
4
Osaic Holdings
4
Osaic Holdings
Arizona
$190K
5
Two Sigma Investments
5
Two Sigma Investments
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
AA
76
Addison Advisors
Vermont
$0 4 – –
BWP
77
Baldwin Wealth Partners
Massachusetts
$0 47 – –
PA
78
Parallel Advisors
California
$0 8 – –
UBS Group
79
UBS Group
Switzerland
$0 9 – –
CFGS
80
Concourse Financial Group Securities
Alabama
– – – –
EI
81
Ellevest Inc
New York
$0 53 +53 New
1 2 3
4